Clinical Trial Update: Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial investigating the effects of empagliflozin on liver fat content, energy metabolism, and body composition in patients with type 2 diabetes, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: The Deutsche Diabetes Forschungsgesellschaft e.V. | Conditions: Type 2 Diabetes, Non-alcoholic Fatty Liver Disease | Phase 4 | Status: COMPLETED